DefenCath Approved to Reduce Incidence of Catheter-Related Bloodstream Infections in Adults
This new drug utilizes the bactericidal properties of taurolidine and the bloodthinning effects of heparin to maintain catheter patency.
FDA Approves Sotagliflozin for Treatment of Heart Failure
NexoBrid for Eschar Removal in Thermal Burns
Anacaulase-bcdb improves current standard of care for deep partial thickness and/or full thickness thermal burns.
FDA Approves Terlipressin for the Management of HRS-1
Approval followed resubmission of data from the phase 3 CONFIRM trial to the agency.
Vivjoa Approved for Recurrent Vulvovaginal Candidiasis
Oteseconazole is a treatment option for those living with a previously unmet medical need.
Molnupiravir: Oral Antiviral for the Treatment of COVID-19
Molnupiravir is an oral antiviral for the treatment of mild to moderate COVID-19 in adults at high risk of severe disease.
Paxlovid: Oral Antiviral for the Treatment of COVID-19
Pfizer received an emergency use authorization (EUA) for Paxlovid, an oral pill for the treatment of mild to moderate COVID-19 in certain adult and pediatric populations.
New Drug Review: Atogepant FDA-Approved for Migraine Treatment
On September 28, the FDA granted approval to oral atogepant (Qulipta) for the prevention of migraine.